{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T21:30:20Z","timestamp":1794778220175,"version":"4.9.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["2093"],"award-info":[{"award-number":["2093"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mater Sci: Mater Med"],"DOI":"10.1007\/s10856-026-07017-2","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:47:38Z","timestamp":1771598858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Asal","family":"Katebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Riazi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ahangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Ajdary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"7017_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202301339","volume":"10","author":"H Dong","year":"2023","unstructured":"Dong H, Li Q, Zhang Y, Ding M, Teng Z, Mou Y. Biomaterials facilitating dendritic cell-mediated cancer immunotherapy. Adv Sci. 2023;10:2301339. https:\/\/doi.org\/10.1002\/advs.202301339.","journal-title":"Adv Sci"},{"key":"7017_CR2","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1021\/acsnano.3c10037","volume":"18","author":"Y Hu","year":"2024","unstructured":"Hu Y, Nie W, Lyu L, Zhang X, Wang W, Zhang Y, et al. Tumor-microenvironment-activatable nanoparticle mediating immunogene therapy and M2 macrophage-targeted inhibitor for synergistic cancer immunotherapy. ACS Nano. 2024;18:3295\u2013312. https:\/\/doi.org\/10.1021\/acsnano.3c10037.","journal-title":"ACS Nano"},{"key":"7017_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/cac2.12178","volume":"41","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang M, Wu H-X, Xu R-H. Advancing to the era of cancer immunotherapy. Cancer Commun. 2021;41:803\u201329. https:\/\/doi.org\/10.1002\/cac2.12178.","journal-title":"Cancer Commun"},{"key":"7017_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202314309","volume":"36","author":"M Meng","year":"2024","unstructured":"Meng M, Wu J, Feng Y, Lin L, Chen J, Pang X, et al. A comprehensive strategy based on high clinical translational nanosystem for programmable immunotherapy of triple negative breast cancer. Adv Mater. 2024;36:2314309. https:\/\/doi.org\/10.1002\/adma.202314309.","journal-title":"Adv Mater"},{"key":"7017_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","volume":"40","author":"P Pathria","year":"2019","unstructured":"Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. Trends Immunol. 2019;40:310\u201327. https:\/\/doi.org\/10.1016\/j.it.2019.02.003.","journal-title":"Trends Immunol"},{"key":"7017_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, Chu N-Q, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559\u201363. https:\/\/doi.org\/10.1038\/nature13490.","journal-title":"Nature"},{"key":"7017_CR7","doi-asserted-by":"publisher","unstructured":"Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta. 2014;1845:182\u2013201. https:\/\/doi.org\/10.1016\/j.bbcan.2014.01.004","DOI":"10.1016\/j.bbcan.2014.01.004"},{"key":"7017_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309\u201322. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.022.","journal-title":"Cancer Cell."},{"key":"7017_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/0008-5472.CAN-15-1737","volume":"76","author":"CD Mills","year":"2016","unstructured":"Mills CD, Lenz LL, Harris RA. A breakthrough: macrophage-directed cancer immunotherapy. Cancer Res. 2016;76:513\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1737.","journal-title":"Cancer Res"},{"key":"7017_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bmt.2023.09.001","volume":"5","author":"K Elumalai","year":"2024","unstructured":"Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Technol. 2024;5:109\u201322. https:\/\/doi.org\/10.1016\/j.bmt.2023.09.001.","journal-title":"Biomed Technol"},{"key":"7017_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jconrel.2023.12.007","volume":"365","author":"B-TN Dang","year":"2024","unstructured":"Dang B-TN, Kwon TK, Lee S, Jeong J-H, Yook S. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy. J Control Release. 2024;365:773\u2013800. https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.007.","journal-title":"J Control Release"},{"key":"7017_CR12","doi-asserted-by":"publisher","unstructured":"PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505\u201322. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.043.","DOI":"10.1016\/j.jconrel.2012.01.043"},{"key":"7017_CR13","doi-asserted-by":"publisher","unstructured":"Pandey A, Jain DS. Poly lactic-co-glycolic acid (PLGA) copolymer and its pharmaceutical application. John Wiley & Sons. 2015. p. 151\u201372. https:\/\/doi.org\/10.1002\/9781119041412.ch6.","DOI":"10.1002\/9781119041412.ch6"},{"key":"7017_CR14","doi-asserted-by":"publisher","unstructured":"Poly(I: C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm. 2009;365:61\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.08.039.","DOI":"10.1016\/j.ijpharm.2008.08.039"},{"key":"7017_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2022.152317","volume":"228","author":"K Pondman","year":"2023","unstructured":"Pondman K, Le Gac S, Kishore U. Nanoparticle-induced immune response: health risk versus treatment opportunity? Immunobiology. 2023;228:152317. https:\/\/doi.org\/10.1016\/j.imbio.2022.152317.","journal-title":"Immunobiology"},{"key":"7017_CR16","doi-asserted-by":"publisher","first-page":"6918","DOI":"10.1021\/acsnano.5b01042","volume":"9","author":"Y Guo","year":"2015","unstructured":"Guo Y, Wang D, Song Q, Wu T, Zhuang X, Bao Y, et al. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano. 2015;9:6918\u201333. https:\/\/doi.org\/10.1021\/acsnano.5b01042.","journal-title":"ACS Nano"},{"key":"7017_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1039\/D1BM01664D","volume":"10","author":"N Khatoon","year":"2022","unstructured":"Khatoon N, Zhang Z, Zhou C, Chu M. Macrophage membrane-coated nanoparticles: a biomimetic approach for enhanced and targeted delivery. Biomater Sci. 2022;10:1193\u2013208. https:\/\/doi.org\/10.1039\/D1BM01664D.","journal-title":"Biomater Sci"},{"key":"7017_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202003559","volume":"30","author":"W-L Liu","year":"2020","unstructured":"Liu W-L, Zou M-Z, Qin S-Y, Cheng Y-J, Ma Y-H, Sun Y-X, et al. Recent advances of cell membrane-coated nanomaterials for biomedical applications. Adv Funct Mater.2020;30:2003559. https:\/\/doi.org\/10.1002\/adfm.202003559.","journal-title":"Adv Funct Mater."},{"key":"7017_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.immuni.2011.04.008","volume":"34","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity. 2011;34:466\u201378. https:\/\/doi.org\/10.1016\/j.immuni.2011.04.008.","journal-title":"Immunity"},{"key":"7017_CR20","doi-asserted-by":"publisher","first-page":"7738","DOI":"10.1021\/acsnano.6b03148","volume":"10","author":"H Cao","year":"2016","unstructured":"Cao H, Dan Z, He X, Zhang Z, Yu H, Yin Q, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016;10:7738\u201348. https:\/\/doi.org\/10.1021\/acsnano.6b03148.","journal-title":"ACS Nano"},{"key":"7017_CR21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1039\/D0BM01164A","volume":"9","author":"M Wang","year":"2021","unstructured":"Wang M, Xin Y, Cao H, Li W, Hua Y, Webster TJ, et al. Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery. Biomater Sci. 2021;9:1088\u2013103. https:\/\/doi.org\/10.1039\/D0BM01164A.","journal-title":"Biomater Sci"},{"key":"7017_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202101349","volume":"11","author":"D Wang","year":"2022","unstructured":"Wang D, Wang S, Zhou Z, Bai D, Zhang Q, Ai X, et al. White blood cell membrane-coated nanoparticles: recent development and medical applications. Adv Healthc Mater 2022;11:2101349. https:\/\/doi.org\/10.1002\/adhm.202101349.","journal-title":"Adv Healthc Mater"},{"key":"7017_CR23","doi-asserted-by":"publisher","unstructured":"Biomimetic platelet membrane-coated nanoparticles for targeted therapy. Eur J Pharm Biopharm. 2022;172:1\u201315. https:\/\/doi.org\/10.1016\/j.ejpb.2022.01.004.","DOI":"10.1016\/j.ejpb.2022.01.004"},{"key":"7017_CR24","doi-asserted-by":"publisher","unstructured":"Enhancement of the anticancer potential and biosafety of BSA-modified, bacterial membrane-coated curcumin nanoparticles. Colloids Surf B Biointerfaces. 2024;243:114156. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.114156.","DOI":"10.1016\/j.colsurfb.2024.114156"},{"key":"7017_CR25","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c02724","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhi S, Ou J, Gao J, Zheng L, Huang M, et al. Cancer cell membrane-coated nanoparticle co-loaded with photosensitizer and toll-like receptor 7 agonist for the enhancement of combined tumor immunotherapy. ACS Nano. 2023. https:\/\/doi.org\/10.1021\/acsnano.3c02724.","journal-title":"ACS Nano"},{"key":"7017_CR26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423\u201337. https:\/\/doi.org\/10.1038\/nm.3394.","journal-title":"Nat Med."},{"key":"7017_CR27","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.7150\/thno.108875","volume":"15","author":"M Khan","year":"2025","unstructured":"Khan M, Ullah R, Wang G, Chu M. Macrophage membrane-functionalized nanotherapeutics for tumor targeted therapy. Theranostics. 2025;15:4823\u201347. https:\/\/doi.org\/10.7150\/thno.108875.","journal-title":"Theranostics"},{"key":"7017_CR28","doi-asserted-by":"publisher","first-page":"9610","DOI":"10.1021\/acsami.6b00853","volume":"8","author":"M Xuan","year":"2016","unstructured":"Xuan M, Shao J, Dai L, Li J, He Q. Macrophage cell membrane camouflaged au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces. 2016;8:9610\u20138. https:\/\/doi.org\/10.1021\/acsami.6b00853.","journal-title":"ACS Appl Mater Interfaces"},{"key":"7017_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2022.5371","volume":"61","author":"J Zhou","year":"2022","unstructured":"Zhou J, Xu Y, Wang G, Mei T, Yang H, Liu Y. The TLR7\/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer. Int J Oncol. 2022;61:1\u201311. https:\/\/doi.org\/10.3892\/ijo.2022.5371.","journal-title":"Int J Oncol."},{"key":"7017_CR30","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","volume":"16","author":"X Sun","year":"2021","unstructured":"Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, et al. Amplifying STING activation by cyclic dinucleotide\u2013manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021;16:1260\u201370. https:\/\/doi.org\/10.1038\/s41565-021-00962-9.","journal-title":"Nat Nanotechnol"},{"key":"7017_CR31","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.3390\/cancers13112695","volume":"13","author":"A Amouzegar","year":"2021","unstructured":"Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING agonists as cancer therapeutics. Cancers. 2021;13:2695 https:\/\/doi.org\/10.3390\/cancers13112695.","journal-title":"Cancers"},{"key":"7017_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112538","volume":"138","author":"A Katebi","year":"2024","unstructured":"Katebi A, Riazi-rad F, Varshochian R, Ajdary S. PLGA nanoparticle-delivered Leishmania antigen and TLR agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB\/c mice. Int Immunopharmacol. 2024;138:112538. https:\/\/doi.org\/10.1016\/j.intimp.2024.112538.","journal-title":"Int Immunopharmacol"},{"key":"7017_CR33","first-page":"45","volume":"62","author":"I Rivolta","year":"2011","unstructured":"Rivolta I, Panariti A, Lettiero B, Sesana S, Gasco P, Gasco MR, et al. Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles. J Physiol Pharmacol. 2011;62:45\u201353.","journal-title":"J Physiol Pharmacol"},{"key":"7017_CR34","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1039\/D0NA00572J","volume":"2","author":"J Hwang","year":"2020","unstructured":"Hwang J, Zheng M, Wiraja C, Cui M, Yang L, Xu C. Reprogramming of macrophages with macrophage cell membrane-derived nanoghosts. Nanoscale Adv. 2020;2:5254\u201362. https:\/\/doi.org\/10.1039\/D0NA00572J.","journal-title":"Nanoscale Adv"},{"key":"7017_CR35","doi-asserted-by":"publisher","first-page":"24442","DOI":"10.1021\/acsami.1c01453","volume":"13","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chen Y, Li J, Zhu X, Liu Y, Wang X, et al. Development of toll-like receptor agonist-loaded nanoparticles as precision immunotherapy for reprogramming tumor-associated macrophages. ACS Appl Mater Interfaces. 2021;13:24442\u201352. https:\/\/doi.org\/10.1021\/acsami.1c01453.","journal-title":"ACS Appl Mater Interfaces"},{"key":"7017_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611\u201322. https:\/\/doi.org\/10.1373\/clinchem.2008.112797.","journal-title":"Clin Chem"},{"key":"7017_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT Method. Methods. 2001;25:402\u20138. https:\/\/doi.org\/10.1006\/meth.2001.1262.","journal-title":"Methods"},{"key":"7017_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/jbm.a.35927","volume":"105","author":"L Rao","year":"2017","unstructured":"Rao L, He Z, Meng Q-F, Zhou Z, Bu L-L, Guo S-S, et al. Effective cancer targeting and imaging using macrophage membrane-camouflaged upconversion nanoparticles. J Biomed Mater Res Part A. 2017;105:521\u201330. https:\/\/doi.org\/10.1002\/jbm.a.35927.","journal-title":"J Biomed Mater Res Part A"},{"key":"7017_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-021-02004-5","volume":"4","author":"SC Jang","year":"2021","unstructured":"Jang SC, Economides KD, Moniz RJ, Sia CL, Lewis N, McCoy C, et al. ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance. Commun Biol. 2021;4:1\u201317. https:\/\/doi.org\/10.1038\/s42003-021-02004-5.","journal-title":"Commun Biol"},{"key":"7017_CR40","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1021\/acsnano.7b08355","volume":"12","author":"D Wang","year":"2018","unstructured":"Wang D, Dong H, Li M, Cao Y, Yang F, Zhang K, et al. Erythrocyte\u2013cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal\/chemotherapy of melanoma. ACS Nano. 2018;12:5241\u201352. https:\/\/doi.org\/10.1021\/acsnano.7b08355.","journal-title":"ACS Nano"},{"key":"7017_CR41","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1021\/acs.molpharmaceut.4c00950","volume":"22","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Pei L, Liu B, Mao Z, Niu Y, Li S, et al. Macrophage membrane-coated nanomedicine enhances cancer immunotherapy by activating macrophages and T cells. Mol Pharm. 2025;22:2402\u201312. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00950.","journal-title":"Mol Pharm"},{"key":"7017_CR42","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1021\/acs.nanolett.7b05263","volume":"18","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Cai K, Li C, Guo Q, Chen Q, He X, et al. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy. Nano Lett. 2018;18:1908\u201315. https:\/\/doi.org\/10.1021\/acs.nanolett.7b05263.","journal-title":"Nano Lett"},{"key":"7017_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111276","volume":"137","author":"A Katebi","year":"2021","unstructured":"Katebi A, Varshochian R, Riazi-rad F, Ganjalikhani-Hakemi M, Ajdary S. Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation. Biomedicine Pharmacother. 2021;137:111276. https:\/\/doi.org\/10.1016\/j.biopha.2021.111276.","journal-title":"Biomedicine Pharmacother"},{"key":"7017_CR44","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09737","volume":"470","author":"SP Kasturi","year":"2011","unstructured":"Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470:543\u20137. https:\/\/doi.org\/10.1038\/nature09737.","journal-title":"Nature"},{"key":"7017_CR45","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1021\/ac4007057","volume":"85","author":"W Hyk","year":"2013","unstructured":"Hyk W, Stojek Z. Quantifying uncertainty of determination by standard additions and serial dilutions methods taking into account standard uncertainties in both axes. Anal Chem. 2013;85:5933\u20139. https:\/\/doi.org\/10.1021\/ac4007057.","journal-title":"Anal Chem"},{"key":"7017_CR46","doi-asserted-by":"crossref","unstructured":"Clarke RG, Lund EK, Johnson IT, Pinder AC. Apoptosis can be detected in attached colonic adenocarcinoma HT29 cells using annexin V binding, but not by TUNEL assay or sub-G0 DNA content. Cytometry. 2000;39:141\u201350.","DOI":"10.1002\/(SICI)1097-0320(20000201)39:2<141::AID-CYTO7>3.0.CO;2-O"},{"key":"7017_CR47","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1083\/jcb.66.1.188","volume":"66","author":"A Krishan","year":"1975","unstructured":"Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66:188\u201393. https:\/\/doi.org\/10.1083\/jcb.66.1.188.","journal-title":"J Cell Biol"},{"key":"7017_CR48","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nnano.2016.168","volume":"11","author":"S Zanganeh","year":"2016","unstructured":"Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11:986\u201394. https:\/\/doi.org\/10.1038\/nnano.2016.168.","journal-title":"Nat Nanotechnol"},{"key":"7017_CR49","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.celrep.2016.04.084","volume":"15","author":"A-M Georgoudaki","year":"2016","unstructured":"Georgoudaki A-M, Prokopec KE, Boura VF, Hellqvist E, Sohn S, \u00d6stling J, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15:2000\u201311. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.084.","journal-title":"Cell Rep"},{"key":"7017_CR50","doi-asserted-by":"publisher","first-page":"6981","DOI":"10.1039\/C5NR07588B","volume":"8","author":"S Krishnamurthy","year":"2016","unstructured":"Krishnamurthy S, Gnanasammandhan MK, Xie C, Huang K, Cui MY, Chan JM. Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. Nanoscale. 2016;8:6981\u20135. https:\/\/doi.org\/10.1039\/C5NR07588B.","journal-title":"Nanoscale"},{"key":"7017_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","volume":"52","author":"SM Moghimi","year":"2012","unstructured":"Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2012;52:481\u2013503. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010611-134623.","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"7017_CR52","doi-asserted-by":"publisher","unstructured":"Zhang S, Chen W, Zhou Y, Zheng X, Fu Y, Liu H, et al. Intelligent nanoplatform integrating macrophage and cancer cell membrane for synergistic chemodynamic\/immunotherapy\/photothermal therapy of breast cancer. ACS Appl Mater Interfaces. 2023 [cited 2025 Mar 15]; https:\/\/doi.org\/10.1021\/acsami.3c12560.","DOI":"10.1021\/acsami.3c12560"},{"key":"7017_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101716","volume":"32","author":"P Grav\u00e1n","year":"2025","unstructured":"Grav\u00e1n P, Marchal JA, Galisteo-Gonz\u00e1lez F. Improving tumor treatment: cell membrane-coated nanoparticles for targeted therapies. Mater Today Bio. 2025;32:101716. https:\/\/doi.org\/10.1016\/j.mtbio.2025.101716.","journal-title":"Mater Today Bio"},{"key":"7017_CR54","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/adhm.201500129","volume":"4","author":"M Xuan","year":"2015","unstructured":"Xuan M, Shao J, Dai L, He Q, Li J. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Health Mater. 2015;4:1645\u201352. https:\/\/doi.org\/10.1002\/adhm.201500129.","journal-title":"Adv Health Mater"},{"key":"7017_CR55","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/pharmaceutics15092243","volume":"15","author":"J Zhang","year":"2023","unstructured":"Zhang J, Gu B, Wu S, Liu L, Gao Y, Yao Y, et al. M1 macrophage-biomimetic targeted nanoparticles containing oxygen self-supplied enzyme for enhancing the chemotherapy. Pharmaceutics. 2023;15:2243 https:\/\/doi.org\/10.3390\/pharmaceutics15092243.","journal-title":"Pharmaceutics"},{"key":"7017_CR56","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2:578 https:\/\/doi.org\/10.1038\/s41551-018-0236-8.","journal-title":"Nat Biomed Eng"},{"key":"7017_CR57","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.1c00209","author":"B Wei","year":"2021","unstructured":"Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo X, et al. Polarization of tumor-associated macrophages by nanoparticle-loaded Escherichia coli combined with immunogenic cell death for cancer immunotherapy. Nano Lett. 2021. https:\/\/doi.org\/10.1021\/acs.nanolett.1c00209.","journal-title":"Nano Lett"},{"key":"7017_CR58","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41467-023-36321-6","volume":"14","author":"V Turco","year":"2023","unstructured":"Turco V, Pfleiderer K, Hunger J, Horvat NK, Karimian-Jazi K, Schregel K, et al. T cell-independent eradication of experimental glioma by intravenous TLR7\/8-agonist-loaded nanoparticles. Nat Commun. 2023;14:771 https:\/\/doi.org\/10.1038\/s41467-023-36321-6.","journal-title":"Nat Commun"},{"key":"7017_CR59","doi-asserted-by":"publisher","unstructured":"Polymeric nanoparticles encapsulating novel TLR7\/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 2018;164:38\u201353. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.02.034.","DOI":"10.1016\/j.biomaterials.2018.02.034"},{"key":"7017_CR60","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b09041","author":"R Yang","year":"2018","unstructured":"Yang R, Xu J, Xu L, Sun X, Chen Q, Zhao Y, et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano. 2018. https:\/\/doi.org\/10.1021\/acsnano.7b09041.","journal-title":"ACS Nano"},{"key":"7017_CR61","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1021\/jm4004957","volume":"57","author":"CE Schiaffo","year":"2014","unstructured":"Schiaffo CE, Shi C, Xiong Z, Olin M, Ohlfest JR, Aldrich CC, et al. Structure\u2013activity relationship analysis of imidazoquinolines with toll-like receptors 7 and 8 selectivity and enhanced cytokine induction. J Med Chem Am Chem Soc. 2014;57:339\u201347. https:\/\/doi.org\/10.1021\/jm4004957.","journal-title":"J Med Chem Am Chem Soc"},{"key":"7017_CR62","doi-asserted-by":"publisher","unstructured":"Cheng N, Watkins-Schulz R, Junkins RD, David CN, Johnson BM, Montgomery SA, et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1\u2013insensitive models of triple-negative breast cancer. JCI Insight. 2018;3:e120638. https:\/\/doi.org\/10.1172\/jci.insight.120638.","DOI":"10.1172\/jci.insight.120638"},{"key":"7017_CR63","doi-asserted-by":"publisher","first-page":"LB-126","DOI":"10.1158\/1538-7445.AM2018-LB-126","volume":"78","author":"N Cheng","year":"2018","unstructured":"Cheng N, Watkins-Schulz R, Junkins R, David C, Johnson BM, Montgomery SA, et al. Abstract LB-126: nanoparticle-incorporated STING activator as an immunotherapeutic for PD-L1 resistant triple-negative breast cancer. Cancer Res. 2018;78:LB-126 https:\/\/doi.org\/10.1158\/1538-7445.AM2018-LB-126.","journal-title":"Cancer Res"},{"key":"7017_CR64","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of sting in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11:1018\u201330. https:\/\/doi.org\/10.1016\/j.celrep.2015.04.031.","journal-title":"Cell Rep"},{"key":"7017_CR65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/imr.12765","volume":"290","author":"BA Flood","year":"2019","unstructured":"Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019;290:24\u201338. https:\/\/doi.org\/10.1111\/imr.12765.","journal-title":"Immunol Rev"},{"key":"7017_CR66","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1021\/acs.molpharmaceut.3c00242","volume":"21","author":"L Bai","year":"2024","unstructured":"Bai L, Liu H, You R, Jiang X, Zhang T, Li Y, et al. Combination nano-delivery systems remodel the immunosuppressive tumor microenvironment for metastatic triple-negative breast cancer therapy. Mol Pharm. 2024;21:2148\u201362. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00242.","journal-title":"Mol Pharm"},{"key":"7017_CR67","doi-asserted-by":"publisher","first-page":"91.30","DOI":"10.4049\/jimmunol.204.Supp.91.30","volume":"204","author":"DR Taylor","year":"2020","unstructured":"Taylor DR, Young K, Korrer MJ. The synergy of TLR and STING in cancer immunity. J Immunol. 2020;204:91.30\u201391.30. https:\/\/doi.org\/10.4049\/jimmunol.204.Supp.91.30.","journal-title":"J Immunol"},{"key":"7017_CR68","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.3390\/cancers14246091","volume":"14","author":"S Bhatnagar","year":"2022","unstructured":"Bhatnagar S, Revuri V, Shah M, Larson P, Shao Z, Yu D, et al. Combination of STING and TLR 7\/8 agonists as vaccine adjuvants for cancer immunotherapy. Cancers. 2022;14:6091 https:\/\/doi.org\/10.3390\/cancers14246091.","journal-title":"Cancers"},{"key":"7017_CR69","doi-asserted-by":"publisher","unstructured":"Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG. Controlled release of antigen and toll-like receptor ligands from PLA-GA nanoparticles enhances immunogenicity. Nanomedicine. 2017 [cited 2024 Nov 6]; https:\/\/doi.org\/10.2217\/nnm-2016-0295.","DOI":"10.2217\/nnm-2016-0295"},{"key":"7017_CR70","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/adfm.201504780","volume":"26","author":"J Su","year":"2016","unstructured":"Su J, Sun H, Meng Q, Yin Q, Tang S, Zhang P, et al. Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv Funct Mater. 2016;26:1243\u201352. https:\/\/doi.org\/10.1002\/adfm.201504780.","journal-title":"Adv Funct Mater"},{"key":"7017_CR71","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1039\/C3NR06371B","volume":"6","author":"BT Luk","year":"2014","unstructured":"Luk BT, Hu CM, Fang RH, Dehaini D, Carpenter C, Gao W, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale. 2014;6:2730\u20137. https:\/\/doi.org\/10.1039\/C3NR06371B.","journal-title":"Nanoscale"},{"key":"7017_CR72","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/djg016","volume":"95","author":"M Sch\u00f6n","year":"2003","unstructured":"Sch\u00f6n M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138\u201349. https:\/\/doi.org\/10.1093\/jnci\/djg016.","journal-title":"J Natl Cancer Inst"},{"key":"7017_CR73","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.3892\/mmr.2015.3885","volume":"12","author":"T Yin","year":"2015","unstructured":"Yin T, He S, Wang Y. Toll\u2011like receptor 7\/8 agonist, R848, exhibits antitumoral effects in a breast cancer model. Mol Med Rep. 2015;12:3515\u201320. https:\/\/doi.org\/10.3892\/mmr.2015.3885.","journal-title":"Mol Med Rep"},{"key":"7017_CR74","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.18632\/oncotarget.1734","volume":"5","author":"S-W Huang","year":"2014","unstructured":"Huang S-W, Kao J-K, Wu C-Y, Wang S-T, Lee H-C, Liang S-M, et al. Targeting aerobic glycolysis and HIF-1\u03b1 expression enhances imiquimod-induced apoptosis in cancer cells. Oncotarget. 2014;5:1363 https:\/\/doi.org\/10.18632\/oncotarget.1734.","journal-title":"Oncotarget"},{"key":"7017_CR75","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jconrel.2023.04.046","volume":"358","author":"T Shen","year":"2023","unstructured":"Shen T, Yang S, Qu X, Chen Z, Zeng L, Sun X, et al. A bionic \u201cTrojan horse\u201d-like gene delivery system hybridized with tumor and macrophage cell membrane for cancer therapy. J Control Release. 2023;358:204\u201318. https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.046.","journal-title":"J Control Release"},{"key":"7017_CR76","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1158\/0008-5472.CAN-15-1885","volume":"76","author":"C-HA Tang","year":"2016","unstructured":"Tang C-HA, Zundell JA, Ranatunga S, Lin C, Nefedova Y, Del Valle JR, et al. Agonist-mediated activation of STING induces apoptosis in malignant B cells. Cancer Res. 2016;76:2137\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1885.","journal-title":"Cancer Res"},{"key":"7017_CR77","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1202797","volume":"2018","author":"S Liu","year":"2018","unstructured":"Liu S, Guan W. STING signaling promotes apoptosis, necrosis, and cell death: an overview and update. Mediators Inflamm. 2018;2018:1202797. https:\/\/doi.org\/10.1155\/2018\/1202797.","journal-title":"Mediators Inflamm"},{"key":"7017_CR78","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/138161210789941793","volume":"16","author":"SY Proskuryakov","year":"2010","unstructured":"Proskuryakov SY, Gabai VL. Mechanisms of tumor cell necrosis. Curr Pharm Des. 2010;16:56\u201368. https:\/\/doi.org\/10.2174\/138161210789941793.","journal-title":"Curr Pharm Des"}],"container-title":["Journal of Materials Science: Materials in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10856-026-07017-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-026-07017-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-026-07017-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:05:35Z","timestamp":1771945535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10856-026-07017-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7017"],"URL":"https:\/\/doi.org\/10.1007\/s10856-026-07017-2","relation":{},"ISSN":["1573-4838"],"issn-type":[{"value":"1573-4838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Pasteur Institute of Iran (IR.PII.REC.1401.013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"41"}}